23 July 2013 | News | By BioSpectrum Bureau
Kerasal Nail (Nalox or Emtrix in certain markets) is a non-prescription product for the treatment of discoloured and deformed nails resulting from fungal infection or psoriasis
Singapore: Menarini Asia Pacific has been granted exclusive rights to market and sell Moberg Pharma's Kerasal Nail in China. The companies now intend to seek marketing authorization for the product in the Chinese market.
Kerasal Nail (Nalox or Emtrix in certain markets) is a non-prescription product for the treatment of discoloured and deformed nails resulting from fungal infection or psoriasis, with a unique mechanism of action that generates visible improvements within two-to-three weeks of treatment.
"We are excited by the opportunity to enter the huge and rapidly expanding
Chinese market. There are challenges related to China's sheer size, business
complexity, regulatory environment and infrastructure. With its profound
understanding of local market conditions, Menarini Asia Pacific is an ideal
partner in this region. The extended agreement enables us to build on our
successful commercial track record together with Menarini," said Mr Peter Wolpert, CEO, Moberg Pharma AB.
"We look forward to introducing Kerasal Nail to Chinese consumers. The product has potential to contribute strongly to our expansion within the Consumer Health market, being a compelling non-prescription product offering rapid visual improvement and an effective solution for patients with nail fungus problems", said Mr John A Graham, CEO, Menarini Asia Pacific.